Literature DB >> 14960500

Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model.

Raúl de la Fuente-Fernández1, Michael Schulzer, Edwin Mak, Donald B Calne, A Jon Stoessl.   

Abstract

Levodopa-treated Parkinson's disease is often complicated by the occurrence of motor fluctuations, which can be predictable ('wearing-off') or unpredictable ('on-off'). In contrast, untreated dopa-responsive dystonia (DRD) is usually characterized by predictable diurnal fluctuation. The pathogenesis of motor fluctuations in treated Parkinson's disease and diurnal fluctuation in untreated DRD is poorly understood. We have developed a mathematical model indicating that all these fluctuations in motor function can be explained by presynaptic mechanisms. The model is predicated upon the release of dopamine being subject to probabilistic variations in the quantity of dopamine released by exocytosis of vesicles. Specifically, we propose that the concentration of intravesicular dopamine undergoes dynamic changes according to a log-normal distribution that is associated with different probabilities of release failure. Changes in two parameters, (i) the proportion of vesicles that undergo exocytosis per unit of time and (ii) the proportion of dopamine subject to re-uptake from the synapse, allowed us to model different curves of levodopa response, for the same degree of nigrostriatal damage in Parkinson's disease. The model predicts the following periods of levodopa clinical benefit: 4 h for stable responders, 3 h for wearing-off fluctuators, and 1.5 h for on-off fluctuators. The model also predicts that diurnal fluctuation in untreated DRD should occur some 8 h after getting up in the morning. All these results fit well with clinical observations. Additionally, we calculated the probability of obtaining a second ON period after a single dose of levodopa in Parkinson's disease (the 'yo-yoing' phenomenon). The model shows that the yo-yoing phenomenon depends on how fast the curve crosses the threshold that separates ON and OFF states, which explains why this phenomenon is virtually exclusive to patients with on-off fluctuations. The model supports the idea that presynaptic mechanisms play a key role in both short-duration and long-duration responses encountered in Parkinson's disease. Dyskinesias may also be explained by the same mechanisms.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14960500     DOI: 10.1093/brain/awh102

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  26 in total

1.  The roles of striatal serotonin and L -amino-acid decarboxylase on L-DOPA-induced Dyskinesia in a Hemiparkinsonian rat model.

Authors:  Sukju Gil; Changhwan Park; Jeongeun Lee; Hyunchul Koh
Journal:  Cell Mol Neurobiol       Date:  2010-03-16       Impact factor: 5.046

2.  Baseline cognitive profile is closely associated with long-term motor prognosis in newly diagnosed Parkinson's disease.

Authors:  Seok Jong Chung; Han Soo Yoo; Hye Sun Lee; Yang Hyun Lee; KyoungWon Baik; Jin Ho Jung; Byoung Seok Ye; Young H Sohn; Phil Hyu Lee
Journal:  J Neurol       Date:  2021-05-04       Impact factor: 4.849

3.  End-of-dose deterioration in non ergolinic dopamine agonist monotherapy of Parkinson's disease.

Authors:  Astrid Thomas; Laura Bonanni; Angelo Di Iorio; Sara Varanese; Francesca Anzellotti; Anna D'Andreagiovanni; Fabrizio Stocchi; Marco Onofrj
Journal:  J Neurol       Date:  2006-12       Impact factor: 4.849

4.  Anatomy of Graft-induced Dyskinesias: Circuit Remodeling in the Parkinsonian Striatum.

Authors:  Kathy Steece-Collier; David J Rademacher; Katherine Soderstrom
Journal:  Basal Ganglia       Date:  2012-02-11

5.  L-Dihydroxyphenylalanine modulates the steady-state expression of mouse striatal tyrosine hydroxylase, aromatic L-amino acid decarboxylase, dopamine and its metabolites in an MPTP mouse model of Parkinson's disease.

Authors:  Jennifer M King; Gladson Muthian; Veronica Mackey; Marquitta Smith; Clivel Charlton
Journal:  Life Sci       Date:  2011-08-18       Impact factor: 5.037

Review 6.  The missing, the short, and the long: Levodopa responses and dopamine actions.

Authors:  Roger L Albin; Daniel K Leventhal
Journal:  Ann Neurol       Date:  2017-06-05       Impact factor: 10.422

7.  Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease.

Authors:  Caroline Moreau; Sayah Meguig; Jean-Christophe Corvol; Julien Labreuche; Francis Vasseur; Alain Duhamel; Arnaud Delval; Thomas Bardyn; Jean-Christophe Devedjian; Nathalie Rouaix; Gregory Petyt; Christine Brefel-Courbon; Fabienne Ory-Magne; Dominique Guehl; Alexandre Eusebio; Valérie Fraix; Pierre-Jean Saulnier; Ouhaid Lagha-Boukbiza; Frank Durif; Mirela Faighel; Caroline Giordana; Sophie Drapier; David Maltête; Christine Tranchant; Jean-Luc Houeto; Bettina Debû; Jean-Philippe Azulay; François Tison; Alain Destée; Marie Vidailhet; Olivier Rascol; Kathy Dujardin; Luc Defebvre; Régis Bordet; Bernard Sablonnière; David Devos
Journal:  Brain       Date:  2015-03-23       Impact factor: 13.501

Review 8.  Functions of the nigrostriatal dopaminergic synapse and the use of neurotransplantation in Parkinson's disease.

Authors:  Alex Tsui; Ole Isacson
Journal:  J Neurol       Date:  2011-05-05       Impact factor: 4.849

9.  Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice.

Authors:  K S Rommelfanger; G L Edwards; K G Freeman; L C Liles; G W Miller; D Weinshenker
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-16       Impact factor: 11.205

10.  Homeostatic mechanisms in dopamine synthesis and release: a mathematical model.

Authors:  Janet A Best; H Frederik Nijhout; Michael C Reed
Journal:  Theor Biol Med Model       Date:  2009-09-10       Impact factor: 2.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.